The "sWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?

Current Oncology Reports

Volumn 13, Issue 6, 2011, Pages 479-487

  Nissan, Moriah H ^a   Solit, David B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

BRAF; ERK; GSK2118436; MAPK; MEK; Melanoma; PLX4032

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; AGENTS AFFECTING METABOLISM; ANTINEOPLASTIC AGENT; B RAF KINASE; BEVACIZUMAB; CAPECITABINE; DACARBAZINE; ENZYME INHIBITOR; GSK 1120212; GSK 2118436; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PEMETREXED; RAF KINASE INHIBITOR; SELUMETINIB; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VEMURAFENIB;

ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER STAGING; CARCINOGENESIS; COLON CANCER; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; EYE TOXICITY; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; KERATOACANTHOMA; KERATOSIS; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MACULOPAPULAR RASH; MELANOMA; MOLECULAR PATHOLOGY; NONHUMAN; ONCOGENE; PANCREAS CANCER; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RASH; RETINA VEIN OCCLUSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; MAP KINASE KINASE KINASES; MELANOMA; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RAF KINASES; SKIN NEOPLASMS;

EID: 81155124389     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-011-0198-4     Document Type: Article

References (55)

1. D Hanahan RA Weinberg 2011 Hallmarks of cancer: the next generation Cell 144 5 646 74 21376230 10.1016/j.cell.2011.02.013 1:CAS:528:DC%2BC3MXjsFeqtrk%3D
2. RJ Davis 1995 Transcriptional regulation by MAP kinases Mol Reprod Dev 42 4 459 67 8607977 10.1002/mrd.1080420414 1:CAS:528:DyaK2MXpvVGisbo%3D
3. CA Pratilas, et al. 2009 (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway Proc Natl Acad Sci USA 106 11 4519 24 19251651 10.1073/pnas.0900780106 1:CAS:528:DC%2BD1MXjslGlurY%3D
4. RE Board, et al. 2009 Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study Br J Cancer 101 10 1724 30 19861964 10.1038/sj.bjc.6605371 1:CAS:528:DC%2BD1MXhtl2hs7rP
5. C Dong, et al. 1996 SOS phosphorylation and disassociation of the Grb2-SOS complex by the ERK and JNK signaling pathways J Biol Chem 271 11 6328 32 10.1074/jbc.271.11.6328 (Pubitemid 26095440)
6. ST Eblen, et al. 2004 Mitogen-activated protein kinase feedback phosphorylation regulates MEK1 complex formation and activation during cellular adhesion Mol Cell Biol 24 6 2308 17 14993270 10.1128/MCB.24.6.2308-2317.2004 1:CAS:528:DC%2BD2cXitVWqsbc%3D (Pubitemid 38325987)
7. IC Northwood, et al. 1991 Isolation and characterization of two growth factor-stimulated protein kinases that phosphorylate the epidermal growth factor receptor at threonine 669 J Biol Chem 266 23 15266 76 1651322 1:CAS:528:DyaK38Xjs1Kmsg%3D%3D (Pubitemid 21907644)
8. D Vigil, et al. 2010 Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer 10 12 842 57 21102635 10.1038/nrc2960 1:CAS:528:DC%2BC3cXhsVOrsbrM
9. CK Weber, et al. 2001 Active Ras induces heterodimerization of cRaf and BRaf Cancer Res 61 9 3595 8 11325826 1:CAS:528:DC%2BD3MXjsFCgtLk%3D (Pubitemid 32694968)
10. PT Wan, et al. 2004 Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 6 855 67 15035987 10.1016/S0092-8674(04)00215-6 1:CAS:528:DC%2BD2cXivVyksLw%3D (Pubitemid 38410730)
11. DM Owens SM Keyse 2007 Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases Oncogene 26 22 3203 13 17496916 10.1038/sj.onc.1210412 1:CAS:528:DC%2BD2sXlt1WktL0%3D (Pubitemid 46763015)
12. HJ Kim D Bar-Sagi 2004 Modulation of signalling by Sprouty: a developing story Nat Rev Mol Cell Biol 5 6 441 50 15173823 10.1038/nrm1400 1:CAS:528:DC%2BD2cXksVarsLg%3D (Pubitemid 38745494)
13. CA Pratilas DB Solit 2010 Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response Clin Cancer Res 16 13 3329 34 20472680 10.1158/1078-0432.CCR-09-3064 1:CAS:528:DC%2BC3cXot1Wlsbw%3D
14. D Chitale, et al. 2009 An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors Oncogene 28 31 2773 83 19525976 10.1038/onc.2009.135 1:CAS:528:DC%2BD1MXnt1Sht7c%3D
15. H Davies, et al. 2002 Mutations of the BRAF gene in human cancer Nature 417 6892 949 54 12068308 10.1038/nature00766 1:CAS:528:DC%2BD38XkvVagsLo%3D (Pubitemid 34716871)
16. JA Curtin, et al. 2005 Distinct sets of genetic alterations in melanoma N Engl J Med 353 20 2135 47 16291983 10.1056/NEJMoa050092 1:CAS:528: DC%2BD2MXht1ajtLjP (Pubitemid 41653105)
17. WS Samowitz, et al. 2005 Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers Cancer Res 65 14 6063 9 16024606 10.1158/0008-5472.CAN-05-0404 1:CAS:528:DC%2BD2MXmt1ehtLY%3D (Pubitemid 40994390)
18. N Dhomen, et al. 2009 Oncogenic Braf induces melanocyte senescence and melanoma in mice Cancer Cell 15 4 294 303 19345328 10.1016/j.ccr.2009.02.022 1:CAS:528:DC%2BD1MXlsFyrtLw%3D
19. PM Pollock, et al. 2003 High frequency of BRAF mutations in nevi Nat Genet 33 1 19 20 12447372 10.1038/ng1054 1:CAS:528:DC%2BD38XpvVeqsrg%3D (Pubitemid 36068675)
20. E Vakiani RK Yantiss 2009 Pathologic features and biologic importance of colorectal serrated polyps Adv Anat Pathol 16 2 79 91 19550369 10.1097/PAP.0b013e31819923b3 1:CAS:528:DC%2BD1MXitFKitrg%3D
21. D Dankort, et al. 2007 A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors Genes Dev 21 4 379 84 17299132 10.1101/gad.1516407 1:CAS:528:DC%2BD2sXisFGns70%3D
22. EE Patton, et al. 2005 BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma Curr Biol 15 3 249 54 15694309 10.1016/j.cub.2005.01.031 1:CAS:528:DC%2BD2MXhtV2lu78%3D (Pubitemid 40205706)
23. D Dankort, et al. 2009 Braf(V600E) cooperates with Pten loss to induce metastatic melanoma Nat Genet 41 5 544 52 19282848 10.1038/ng.356 1:CAS:528:DC%2BD1MXjtFCisbY%3D
24. SM Wilhelm, et al. 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 19 7099 109 15466206 10.1158/0008-5472.CAN-04-1443 1:CAS:528:DC%2BD2cXotFalsbk%3D (Pubitemid 39331023)
25. JW Clark, et al. 2005 Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors Clin Cancer Res 11 15 5472 80 16061863 10.1158/1078-0432.CCR-04-2658 1:CAS:528:DC%2BD2MXmvFSmtbY%3D (Pubitemid 41060823)
26. G Bollag, et al. 2010 Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 467 7315 596 9 20823850 10.1038/nature09454 1:CAS:528:DC%2BC3cXht1ajtbfK
27. KT Flaherty, et al. 2010 Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 9 809 19 20818844 10.1056/NEJMoa1002011 1:CAS:528:DC%2BC3cXhtVyksb3M This manuscript reports the first in-patient phase 1 trial of the RAF inhibitor PLX4032. In this trial, PLX4032 had an 81% response rate in patients with melanoma whose tumors expressed a BRAF mutation
28. Chapman PB, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011.
29. EW Joseph, et al. 2010 The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner Proc Natl Acad Sci USA 107 33 14903 8 20668238 10.1073/pnas.1008990107 1:CAS:528: DC%2BC3cXhtVOjsLrP
30. PI Poulikakos, et al. 2010 RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 464 7287 427 30 20179705 10.1038/nature08902 1:CAS:528:DC%2BC3cXjsFWjsrs%3D This study demonstrates that the paradoxical activation of MAPK pathway signaling by PLX4032 observed in BRAF wild-type cells is mediated by the formation of RAF-dimers
31. SJ Heidorn, et al. 2010 Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF Cell 140 2 209 21 20141835 10.1016/j.cell.2009.12.040 1:CAS:528:DC%2BC3cXkvVWitL0%3D
32. G Hatzivassiliou, et al. 2010 RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth Nature 464 7287 431 5 20130576 10.1038/nature08833 1:CAS:528:DC%2BC3cXhsVygtb8%3D
33. R Halaban, et al. 2010 PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells Pigment Cell Melanoma Res 23 2 190 200 20149136 10.1111/j.1755-148X.2010.00685.x 1:CAS:528:DC%2BC3cXltF2ls7s%3D
34. PM LoRusso, et al. 2010 Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers Clin Cancer Res 16 6 1924 37 20215549 10.1158/1078-0432.CCR-09-1883 1:CAS:528:DC%2BC3cXjtFyhurk%3D
35. Kefford R, Arkenau H, Brown MP, Millward M, Infante JR, Long GV, Ouellet D, Curtis M, Lebowitz PF, Falchook GS. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010;28.
36. DB Solit, et al. 2006 BRAF mutation predicts sensitivity to MEK inhibition Nature 439 7074 358 62 16273091 10.1038/nature04304 1:CAS:528:DC%2BD28XkvF2mtw%3D%3D (Pubitemid 43128863)
37. CA Pratilas, et al. 2008 Genetic predictors of MEK dependence in non-small cell lung cancer Cancer Res 68 22 9375 83 19010912 10.1158/0008-5472.CAN-08-2223 1:CAS:528:DC%2BD1cXhtlOmt7vL
38. E Halilovic, et al. 2010 PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling Cancer Res 70 17 6804 14 20699365 10.1158/0008-5472.CAN-10-0409 1:CAS:528:DC%2BC3cXhtV2rsLbJ
39. PM Lorusso, et al. 2005 Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies J Clin Oncol 23 23 5281 93 16009947 10.1200/JCO.2005.14.415 1:CAS:528:DC%2BD2MXpslOrtL8%3D (Pubitemid 46206982)
40. AP Brown, et al. 2007 Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration Cancer Chemother Pharmacol 59 5 671 9 16944149 10.1007/s00280-006-0323-5 1:CAS:528:DC%2BD2sXhvVeitbY%3D (Pubitemid 46295133)
41. Dummer R, Robert C, Chapman PB, Sosman JA, Middleton M, Bastholt L, Kemsley K, Cantarini MV, Morris C, Kirkwood JM. AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: an open-label, randomized, multicenter, phase II study. J Clin Oncol 2008;26.
42. Tzekova V, Cebotaru C, Ciuleanu TE, Damjanov D, Ganchev H, Kanarev V, Stella PJ, Sanders N, Pover G, Hainsworth JD. Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008;26(15S).
43. Lang I, Adenis A, Boer K, Escudero P, Kim T, Valladares M, Sanders N, Pover G, Douillard J. AZD6244 (ARRY-142886) versus capecitabine (CAP) in patients (pts) with metastatic colorectal cancer (mCRC) who have failed prior chemotherapy. J Clin Oncol 2008;26.
44. Infante JR, Fecher LA, Nallapareddy S, Gordon Ms, Flaherty KT, Cox DS, DeMarini DJ, Morris SR, Burris HA, Messersmith WA. Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. J Clin Oncol 2010;28(15s).
45. JA Engelman, et al. 2008 Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers Nat Med 14 12 1351 6 19029981 10.1038/nm.1890 1:CAS:528:DC%2BD1cXhsVWhu7rI
46. QB She, et al. 2010 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors Cancer Cell 18 1 39 51 20609351 10.1016/j.ccr.2010.05.023 1:CAS:528: DC%2BC3cXpslSjt7k%3D
47. D Solit CL Sawyers 2010 Drug discovery: how melanomas bypass new therapy Nature 468 7326 902 3 21164474 10.1038/468902a 1:CAS:528:DC%2BC3cXhsFKmu7nF
48. S Whittaker, et al. 2010 Gatekeeper mutations mediate resistance to BRAF-targeted therapies Sci Transl Med 2 35 35ra41 20538618 10.1126/ scitranslmed.3000758
49. R Nazarian, et al. 2010 Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 468 7326 973 7 21107323 10.1038/nature09626 1:CAS:528:DC%2BC3cXhsVOrsbjI
50. Wagle N et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011.
51. C Montagut, et al. 2008 Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma Cancer Res 68 12 4853 61 18559533 10.1158/0008-5472.CAN-07-6787 1:CAS:528:DC%2BD1cXnt1ejsbs%3D
52. CM Johannessen, et al. 2010 COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Nature 468 7326 968 72 21107320 10.1038/nature09627 1:CAS:528:DC%2BC3cXhsVOrsLvP
53. J Villanueva, et al. 2010 Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K Cancer Cell 18 6 683 95 21156289 10.1016/j.ccr.2010.11.023 1:CAS:528:DC%2BC3cXhsFGhsbjJ
54. YN Gopal, et al. 2010 Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells Cancer Res 70 21 8736 47 20959481 10.1158/0008-5472. CAN-10-0902 1:CAS:528:DC%2BC3cXhtlKjt7%2FJ
55. FS Hodi, et al. 2010 Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 8 711 23 20525992 10.1056/NEJMoa1003466 1:CAS:528:DC%2BC3cXhtVCrtrbN